Incidence of hypersensitivity reactions (HSR) in patients receiving reduced doses of dexamethasone as prophylaxis for carboplatin and paclitaxel in gynecologic malignancies

被引：0
|
作者：
Liauw, Justin [1 ]
Darus, Christopher [1 ]
Allen, Diane [1 ]
Snow, Amanda [1 ]
Kapeelmen, Alexander [1 ]
机构：
[1] Maine Med Ctr, Portland, ME 04102 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps9663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9663
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel
    Fader, Amanda N.
    Rose, Peter G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (07) : 1281 - 1283
  • [22] A retrospective review on extended carboplatin infusion and incidence of hypersensitivity reaction in gynecologic malignancies in a single institution.
    Park, Jennifer
    Lee, Matthew Z.
    Kockenmeister, Erik
    John, Veena S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies
    Robinson, JB
    Singh, D
    Bodurka-Bevers, DC
    Wharton, JT
    Gershenson, DM
    Wolf, JK
    GYNECOLOGIC ONCOLOGY, 2001, 82 (03) : 550 - 558
  • [24] Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy
    Xiao, Di
    Yang, Zhiyun
    Shi, Yin
    Yang, Wenqing
    Zhang, Yu
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (5-6) : 525 - 532
  • [25] Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies
    O'Cathail, Sean M.
    Shaboodien, Roekshana
    Mahmoud, Sarah
    Carty, Karen
    O'Sullivan, Patrick
    Blagden, Sarah
    Gabra, Hani
    Whear, Sue
    Kwon, Janice S.
    Agarwal, Roshan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (07) : 1318 - 1325
  • [26] Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel
    Brightwell, R.
    Hande, E.
    Eng, K.
    Grzankowski, K.
    Frederick, P.
    Odunsi, K.
    Lele, S.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (06) : 800 - 802
  • [27] Premedication for prophylaxis of hypersensitivity reactions (HSR) after weekly or 3-weekly paclitaxel (ptx): a comprehensive literature review
    Dewaele, Elien
    Specenier, Pol
    ACTA CLINICA BELGICA, 2016, 71 : 13 - 13
  • [28] Premedication prophylaxis of hypersensitivity reactions (HSR) after weekly or 3-weekly paclitaxel (ptx): a comprehensive literature review
    Dewaele, E.
    Specenier, P.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S165 - S165
  • [29] Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study
    Fuminori Ito
    Naoto Furukawa
    Supportive Care in Cancer, 2017, 25 : 1941 - 1945
  • [30] Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study
    Ito, Fuminori
    Furukawa, Naoto
    SUPPORTIVE CARE IN CANCER, 2017, 25 (06) : 1941 - 1945
12345